<DOC>
	<DOCNO>NCT01695590</DOCNO>
	<brief_summary>To determine maximum tolerate dose , response , PRLX 93936 treatment patient relapse relapsed/refractory multiple myeloma .</brief_summary>
	<brief_title>Safety , Efficacy Pharmacokinetic Study PRLX 93936 Patients With Multiple Myeloma</brief_title>
	<detailed_description>- To determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) PRLX 93936 administer IV 3 day week ( Monday , Wednesday Friday ) 3 week follow 9 day rest period , treatment patient relapse relapsed/refractory multiple myeloma . - To establish dose PRLX 93936 recommend future study . - To characterize potential toxicity PRLX 93936 . - To assess pharmacokinetic profile PRLX 93936 . - To evaluate response treatment , time response ( TTR ) duration response . - To evaluate time progression ( TTP ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Patient must diagnosis multiple myeloma relapse relapsed/refractory disease . Patient must receive ≥ 2 prior antimyeloma regimen include proteasome inhibitor and/or immunomodulatory agent . Patient currently require systemic therapy . Patient measurable disease . Age ≥ 18 year Karnofsky performance status ≥ 60 % ECOG performance 0 , 1 2 Life expectancy least three month Able take acetaminophen Not pregnant Patient must recover toxicity incur result previous antimyeloma therapy recover baseline . Patients receive autologous stem cell transplant must ≥ 3 month posttransplant associate toxicity must resolve ≤ CTCAE Grade 1 . QT interval QTc ≤ 500 msec POEMS syndrome Plasma cell leukemia Primary amyloidosis Patient smolder multiple myeloma monoclonal gammopathy unknown significance ( MGUS ) . Evidence spinal cord compression CNS complication unless control appropriate therapy . Patient receive chemotherapy anticancer therapy may active multiple myeloma within 3 week prior first dose PRLX 93936 . Patient receive nitrosureas within 6 week prior first dose . Patient receive corticosteroid within 2 week prior first dose . Patient receive plasmapheresis within 4 week prior first dose . Patient major surgery within 4 week prior first dose . Patient allogeneic stem cell transplant within 6 month first dose PRLX 93936 evidence graft versus host disease . Patient take therapy concomitantly may active multiple myeloma . Patient currently receive medication ( ) principally metabolize via cytochrome P450 3A4 enzyme pathway . Use investigational agent within 28 day 5 halflives ( whichever short ) study treatment . Patient peripheral neuropathy Grade 3 great intensity , painful Grade 2 , define NCI CTC . Patient myocardial infarction within 6 month enrollment NYHA Class III IV heart failure uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Abnormal LVEF ( &lt; LLN institution patient age ) echocardiogram Patient poorly control hypertension , diabetes mellitus , serious medical psychiatric illness could potentially interfere completion treatment accord protocol . Patient malignancy multiple myeloma within 3 year enrollment , exception adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ breast cancer , situ prostate cancer . Patient 's clinical laboratory value meet follow criterion within 7 day prior Study Day 1 : Bilirubin &gt; 1.5 time ULN AST ( SGOT ) , ALT ( SGPT ) Alkaline phosphatase &gt; 2.5 time ULN Uncontrolled hypercalcemia ( define serum calcium &gt; 14 mg/dL ) Serum creatinine &gt; 2.0 mg/dL creatinine clearance &lt; 30 mL/min ANC &lt; 1000 cells/mm3 &lt; 750 cells/mm3 due &gt; 50 % marrow involvement Platelet count &lt; 50,000 cells/mm3 Hemoglobin &lt; 8.0 g/dL Patient know human immunodeficiency virus ( HIV ) positive . Patient know hepatitis B surface antigenpositive know active hepatitis C infection . Patient active systemic infection require treatment within 14 day first dose PRLX 93936 . Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>PRLX93936</keyword>
</DOC>